Alembic Pharma successfully completes ANVISA, Brazil GMP audit for API-III facility at Karakhadi

Vadodara: Alembic Pharmaceuticals Limited has announced that the Company has successfully completed the Brazilian Health Regulatory Agency (ANVISA) GMP audit at API-III Facility at Karakhadi without any observations for its 56 APIs.

The inspection was conducted from 20th March, 2023 to 24th March, 2023.

Read also: USFDA inspection: Alembic Pharma gets 2 observations for Karkhadi facility

Headquartered in Vadodara, Gujarat, Alembic Pharmaceuticals Limited is involved in manufacturing and marketing India Formulations, International Generics, and Active Pharmaceutical Ingredients with vertical integration capabilities. The company was founded in 1907. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA. Alembic has a cumulative total of 183 ANDA approvals (160 final approvals and 23 tentative approvals) from USFDA.

Read also: Alembic Pharma successfully completes USFDA inspection for Derma Facility at Karakhadi